Direct evidence for central sites of action of zolmitriptan (311C90): An autoradiographic study in cat

Cephalalgia

Volumn 17, Issue 3, 1997, Pages 153-158

  Goadsby, P J ^a,b   Knight, Y E ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cluster headache; migraine; serotonin agonist; treatment; trigeminal nucleus

Indexed keywords

SEROTONIN AGONIST; ZOLMITRIPTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CAT; CONTROLLED STUDY; HEADACHE; MIGRAINE; NONHUMAN; TRIGEMINAL NUCLEUS;

EID: 0030974392     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1997.1703153.x     Document Type: Article

References (51)

1. Goadsby PJ. The challenge of headache for the nineties. Curr Opin Neurol 1994;7:255-82
2. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994;46:157-203
3. Hartig PR, Hoyer D, Humphrey PPA, Martin GR. Alignment of receptor nomenclature with the human genome: classification of 5HT-1B and 5HT-1D receptor subtypes. Trends Pharmacol Sci 1996;17:103-5
4. Ferrari MD. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991;325:316-21
5. Goadsby PJ, Zagami AS, Donnan GA, et al. A double blind placebo controlled crossover study of sumatriptan in the treatment of acute migraine attacks. Lancet 1991;II:782-3
6. Humphrey PPA, Goadsby PJ. Controversies in headache. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-10
7. Wolff HG. Headache and other head pain. New York: Oxford University Press, 1963
8. Lambert GA, Goadsby PJ, Zagami AS, Duckworth JW. Comparative effects of stimulation of the trigeminal ganglion and the superior sagittal sinus on cerebral blood flow and evoked potentials in the cat. Brain Res 1988;453:143-9
9. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-Fos and electrophysiology study. Brain 1996;119:249-56
10. Goadsby PJ, Zagami AS. Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 1991;114:1001-11
11. Kaube H, Keay K, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res 1993;629:95-102
12. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996;119:1419-28
13. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 1988;23:193-6
14. Buzzi MG, Moskowitz MA, Shimizu T, Heath HH. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-200
15. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 1990;16:69-75
16. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7
17. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-90
18. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 1994;117:427-34
19. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increases in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995;60:119-23
20. Kaube H, Hoskin KL, Goadsby PJ. Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-92
21. Shephard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 1995;34:255-61
22. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996;53:180-4
23. 1b binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 1987;243:989-1001
24. 3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991;29:91-4
25. 3H]sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995;280:175-8
26. 1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedeberg's Arch Pharmacol 1995;352:263-75
27. Martin GR. Preclinical profile of the novel 5HT1D receptor agonist 311C90. In: Rose FC, editor. New Advances in Headache Research, Vol. 4. London: Smith-Gordon, 1994:3-4
28. Hill AP, Hyde RM, Robertson AD, Woollard PM, Glen RC, Martin GR. Oral delivery of 5-HT1D receptor agonists: towards the discovery of 311C90, a novel antimigraine agent. Headache 1995;34:308
29. Visser WH, Klein KB, Cox RC, Jones D, Ferrari M. 311C90, a new central and peripherally acting 5HT-1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled dose-range finding study. Neurology 1996;46:522-6
30. Goadsby PJ, Edvinsson L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 1994;34:394-9
31. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996;67:355-9
32. Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the non-human primate brain macaca nemestrina: a c-fos immunocytochemical study. J Anat 1997 (in press)
33. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache 1991;31:365-71
34. Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia 1994;14:320-7
35. Kaube H, Hoskin KL, Goadsby PJ. Lignocaine and headache: an electrophysiological study in the cat with supporting clinical observations in man. J Neurol 1994;241:415-20
36. Kaube H, Hoskin KL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993;33:541-50
37. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan inhibits central trigeminal nociceptive responses in an electrophysiological assay in the anaesthetized rat. In: Olesen J, Edvinsson L, editors. Messenger molecules in headache pathogenesis: monoamines, neuropeptides, purines and nitric oxide. Copenhagen: Proceedings of the 7th International Headache Research Seminar, 1996:18
38. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44:1587-92
39. Nissila M, Parkkola R, Sonninen P, Salonen R. Intracerebral arteries and gadolinium enhancement in migraine without aura. Cephalalgia 1996;16:363
40. Waeber C, Moskowitz MA. [3H]sumatriptan labels both 5-HT1D and 5HT-1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn-Schmiedeberg's Arch Pharmacol 1995;352:263-75
41. Pascual J, del Arco C, Romon T, del Olmo C, Pazos A. [3H] Sumatriptan binding sites in human brain: regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 1996;295:271-4
42. Pauwels PJ, Wurch T, Amoureux MC, Palmier C, Colpaert FC. Stimulation of cloned human serotonin 5-HT1D beta receptor sites in stably transfected C6 glial cells promotes cell growth. J Neurochem 1996;66:65-73
43. 1F receptor agonist, in the neurogenic durai inflammation model of migraine pain. Proc Soc Neurosci (USA) 1996;22:1331
44. Rebeck GW, Maynard KI, Hyman BT, Moskowitz MA. Selective 5HT1D alpha serotonin receptor gene expression in trigeminal ganglion: implications for antimigraine drug development. Proc Natl Acad Sci (USA) 1994;91:3666-9
45. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 1993;33:48-56
46. Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Ann Rev Med 1993;44:145-54
47. Goadsby PJ, Duckworth JW. Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol 1987;253:R270-4
48. Dahlof C, Diener HC, Goadsby PJ, et al. A multicentre, double-blind, placebo-controlled, dose range-finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995;35:292
49. Schoenen J, Proletti Cecchini A, Afra J. Evidence in man for a central of a 5-HT-1D-agonist, 311C90, from a study of the intensity dependence of the cortical evoked potential. Eur J Neurol 1996;3 Suppl 5:88
50. Schoenen J, Klein KB. The CNS adverse event profiles of 311C and Sumatriptan appear identical. Eur J Neurol 1996;3: 153
51. Jackson NC. A comparison of oral eletriptan (UK-116,044) (20-80 mg) and oral sumatriptan (100 mg) in the acute treatment of migraine. Cephalalgia 1996;16:368-9